---
provider: perplexity
model: sonar-deep-research
cached: false
start_time: '2026-04-04T14:53:08.245762'
end_time: '2026-04-04T14:55:04.173303'
duration_seconds: 115.93
template_file: templates/drug_disease_research.md
template_variables:
  disease_name: chromosome 1p36 deletion syndrome
  mondo_id: MONDO:0011929
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    reasoning_effort: medium
    search_domain_filter: []
    return_citations: true
    temperature: 0.0
citation_count: 38
---

## Question

# Drug-Disease Association Research Template

## Target Disease
- **Disease Name:** chromosome 1p36 deletion syndrome
- **MONDO ID:** MONDO:0011929

## Research Objectives

Please provide a comprehensive research report on **drug therapies for chromosome 1p36 deletion syndrome**.
Focus on approved treatments, investigational drugs, repurposing candidates, and off-label uses.

### Required Information

#### 1. Approved Drug Therapies
- What drugs are currently approved for this disease?
- Which regulatory agencies have approved them (FDA, EMA, PMDA, etc.)?
- What is the mechanism of action for each approved drug?

#### 2. Investigational and Pipeline Drugs
- What drugs are currently in clinical trials for this disease?
- What phase are they in (Phase I, II, III, IV)?
- What are the key clinical trial identifiers (NCT numbers)?

#### 3. Drug Repurposing Candidates
- Are there drugs approved for other indications that show promise for this disease?
- What evidence supports their potential use (case reports, off-label experience, preclinical data)?

#### 4. Contraindications
- Which drugs are contraindicated in patients with this disease?
- What is the mechanistic basis for contraindication?

#### 5. Adverse Events of Relevance
- Are there drugs known to cause or worsen this disease as an adverse effect?
- What is the frequency and severity of these adverse effects?

#### 6. Combination Therapies
- Are there established combination therapy regimens?
- What synergistic or additive effects are documented?

### Citation Requirements

- Cite primary literature (PMID preferred) for all claims
- Include clinical trial references (NCT numbers) where applicable
- Prioritize recent systematic reviews, meta-analyses, and landmark clinical trials
- Include direct quotes where possible to support key statements
- For regulatory approvals, reference the specific label or approval document

### Output Format

Structure your response as a narrative report with:
- Drug names (use generic/INN names)
- Disease-drug relationship type (indication, contraindication, adverse event, investigational)
- Evidence strength and source type (clinical trial, case report, regulatory label, etc.)
- PMIDs for all cited literature


## Output

# Comprehensive Analysis of Drug Therapies for Chromosome 1p36 Deletion Syndrome

## Executive Summary

Chromosome 1p36 deletion syndrome, affecting approximately 1 in 5,000 to 1 in 10,000 newborns[2][8], represents the most common terminal deletion syndrome in humans and presents a complex clinical challenge requiring multifaceted pharmacological management. This syndrome is characterized by severe intellectual disability, developmental delay, distinctive facial features, hypotonia, seizures, and multiple congenital anomalies including cardiac defects and neurological abnormalities[2][25]. Currently, no drugs are specifically approved by the FDA or other major regulatory agencies for the treatment of 1p36 deletion syndrome itself; rather, pharmacological management focuses on treating the individual manifestations of the disorder. The therapeutic landscape encompasses approved medications repurposed for symptom management across neurological (antiepileptic drugs, psychotropic medications), cardiac, and behavioral domains, supplemented by emerging investigational compounds targeting the putative molecular mechanisms underlying the syndrome. This report synthesizes available evidence regarding approved pharmacotherapies, investigational agents in development, off-label drug applications, contraindicated medications, and combination treatment strategies, providing a comprehensive resource for clinicians, researchers, and healthcare providers managing patients with this rare chromosomal disorder.

## Pathophysiology and Molecular Basis of 1p36 Deletion Syndrome

### Chromosomal Architecture and Deletion Characteristics

Chromosome 1p36 deletion syndrome results from a heterozygous deletion of genetic material located on the short (p) arm of chromosome 1, with deletions ranging from small segments to large terminal deletions encompassing up to 30 megabases (Mb) of DNA[25][25]. The genetic architecture of the 1p36 region contains numerous repetitive DNA sequences that predispose this region to non-allelic homologous recombination, leading to recurrent deletions[11]. Approximately 50 percent of cases result from de novo terminal deletions affecting the distal tip of chromosome 1p36, around 29 percent involve interstitial deletions, and the remaining cases comprise complex chromosomal rearrangements[2][5]. The variability in deletion size and location directly correlates with phenotypic heterogeneity, as different genomic regions contain distinct genes contributing to specific clinical features[11][21][3].

Critical regions within the 1p36 deletion have been identified through genotype-phenotype correlation studies[3][11][3]. The distal (telomeric) critical regions (chr1:1–6,289,973; OMIM #607872) are most frequently deleted and are associated with cardiac anomalies, brain malformations, and epilepsy[11][11]. These regions contain multiple genes whose haploinsufficiency contributes to the neurological and cardiac phenotypes characterizing the syndrome[25][25]. Several key genes have been identified through functional studies and animal models, including GABRD (encoding the delta subunit of gamma-aminobutyric acid receptor A), KCNAB2 (voltage-gated potassium channel subunit beta-2), SKI (proto-oncogene), PRDM16 (PR domain containing 16), RERE (nuclear receptor coregulator), and others[21][25][25].

### Genetic Basis of Major Clinical Features

The neurodevelopmental abnormalities characteristic of 1p36 deletion syndrome, including intellectual disability, seizures, and developmental delay, arise from haploinsufficiency of several genes involved in neuronal development and function[3][21][21][25]. The GABRD gene, which encodes the GABA-A receptor delta subunit, has been identified as a critical contributor to seizure susceptibility and neurodevelopmental dysfunction, with animal studies demonstrating altered GABAergic signaling in the absence of functional GABRD[6][25]. Similarly, KCNAB2 mutations have been associated with developmental delay, intellectual disability, and seizure predisposition through impaired potassium channel function[21][25][25]. These molecular alterations fundamentally affect neuronal excitability and synaptic plasticity, creating a neurobiological substrate for the cognitive and epileptic manifestations observed clinically[6][6][6][6].

Cardiac involvement in 1p36 deletion syndrome, observed in approximately 70 percent of patients with congenital heart defects and 15 to 23 percent with cardiomyopathies[12], results primarily from haploinsufficiency of the PRDM16 gene, encoding a transcription factor critical for cardiac development[13]. Fine mapping studies identified PRDM16 as the gene responsible for left ventricular noncompaction cardiomyopathy and dilated cardiomyopathy associated with 1p36 deletions[13]. PRDM16 functions in regulating leukemogenesis, palatogenesis, neurogenesis, and brown fat development, and its loss of function impairs proliferative capacity during cardiogenesis[13]. Additionally, RERE haploinsufficiency contributes to congenital heart defects through disruption of retinoic acid signaling, with animal models suggesting a role in cardiac morphogenesis[12][25][25].

## Antiepileptic Drugs for Seizure Management

### Epidemiology of Seizures in 1p36 Deletion Syndrome

Seizures represent one of the most common and clinically significant manifestations of 1p36 deletion syndrome, occurring in approximately 50 to 60 percent of affected individuals[6][6][6]. The seizure phenotypes are highly variable and include infantile spasms (also termed West syndrome), partial or generalized tonic-clonic seizures, myoclonic seizures, typical and atypical absence seizures, and atonic seizures[6][6][6]. Electroencephalographic findings similarly demonstrate heterogeneity, with reports of focal and multifocal spikes, hypsarhythmia, and asymmetry of slow activity[6][6][6]. Of particular clinical significance, infantile spasms in 1p36 deletion syndrome appear to be associated with a higher risk of developing refractory epilepsy compared to other seizure onset presentations[6][6][6].

The pathogenesis of epilepsy in 1p36 deletion syndrome remains incompletely understood but is thought to result from the high gene density of the 1p36 region combined with the variable deletion sizes and genomic breakpoints characteristic of this syndrome[6][6][6]. Multiple genes within the deletion region contribute to seizure susceptibility through haploinsufficiency mechanisms affecting GABAergic and glutamatergic neurotransmission, ion channel function, and neuronal development[6][21][6]. Deletions encompassing critical regions for epilepsy, defined through analysis of affected individuals, substantially elevate seizure risk[6][6][6].

### Standard Antiepileptic Drug Therapy

#### First-Line Agents for Non-Infantile Spasm Seizures

Valproate (valproic acid, VPA) represents one of the most commonly utilized and effective antiepileptic agents for 1p36 deletion syndrome[6][6][6][6]. For focal seizures, generalized seizures, and absence seizures in 1p36 deletion syndrome, VPA is recommended as a first-line option, either as monotherapy or in combination with lamotrigine[6][6][6][6]. The mechanism of action involves inhibition of histone deacetylase and enhancement of GABA-mediated inhibitory neurotransmission, though the precise mechanism accounting for its efficacy in 1p36-associated seizures remains incompletely characterized[6][6][6].

Levetiracetam (LEV) has demonstrated efficacy as both monotherapy and combination therapy for various seizure types in 1p36 deletion syndrome[6][6][6][6]. Unlike traditional antiepileptic drugs, levetiracetam binds to the synaptic vesicle protein 2A, modulating neurotransmitter release through a mechanism distinct from GABAergic enhancement[6][6]. In large cohort studies of patients with Wolf-Hirschhorn syndrome (another chromosomal deletion disorder), levetiracetam was among the most efficacious agents with favorable tolerability, and evidence suggests comparable utility in 1p36 deletion syndrome[6][6][6].

Lamotrigine (LTG), acting as a sodium channel blocker and enhancing GABAergic neurotransmission, has demonstrated efficacy particularly when combined with VPA for focal and generalized seizures[6][6][6][6]. The combination of VPA and LTG is specifically recommended by some experts as a first-line approach for certain seizure types in 1p36 deletion syndrome[6][6][6].

#### Management of Infantile Spasms

Infantile spasms (West syndrome) represents a particularly severe seizure manifestation in 1p36 deletion syndrome, associated with developmental regression and a higher likelihood of progressing to intractable epilepsy[1][6][6][6]. The American Academy of Neurology and Child Neurology Society practice parameters identify adrenocorticotropic hormone (ACTH) and vigabatrin (VGB) as standard first-line therapies for infantile spasms across multiple etiologies[10][27]. Comparative effectiveness studies demonstrate that ACTH achieves freedom from treatment failure in approximately 46 percent of patients, while vigabatrin achieves this endpoint in approximately 37 percent, and nonstandard therapies achieve only 8 percent[27].

ACTH administration in high doses has demonstrated efficient control of infantile spasms in 1p36 deletion syndrome, with response rates generally ranging from 40 to 50 percent depending on dose and treatment duration[6][10][6][6][27]. Natural ACTH gel is preferred in the United States, while synthetic tetracosactide depot is used internationally[10]. For patients initially failing to respond to monotherapy, combination therapy consisting of hormonal treatments (ACTH or oral corticosteroids) in combination with vigabatrin substantially improves outcome, with cessation of spasms occurring in 72 percent of those receiving combination therapy versus 57 percent receiving hormonal treatment alone[10].

Vigabatrin, a selective inhibitor of gamma-aminobutyric acid transaminase leading to increased central nervous system GABA concentrations, represents an alternative or adjunctive approach[6][10][6][6]. Among children with vigabatrin treatment in recent clinical experience, 52 percent demonstrated either early or late response with sustained remission at 12 months, and among responders, 87.5 percent showed no developmental worsening during neurological follow-up[30]. Critical to vigabatrin use is the risk of irreversible peripheral visual field defects, though recent studies suggest this risk may be lower than historically estimated, with three of seven patients with prior cortical vision impairment showing no retinal toxicity despite vigabatrin exposure[30].

Valproate, phenobarbital, topiramate, and levetiracetam have also been employed for infantile spasms in 1p36 deletion syndrome, demonstrating efficacy in some cases[6][6][6][6]. The specific choice among agents may be guided by the seizure type at onset—valproate demonstrates efficacy for atypical absence seizures at infantile spasm presentation, while carbamazepine may be considered for tonic seizures, though this agent carries additional risks discussed subsequently[6][6][6][6].

### Contraindicated or High-Risk Antiepileptic Agents

#### Carbamazepine and Oxcarbazepine

Carbamazepine (CBZ) and oxcarbazepine (OCZ) represent critical contraindications in the treatment of 1p36 deletion syndrome and should be avoided or discontinued in affected patients[6][6][22][6]. Multiple clinical case reports and mechanistic studies demonstrate that these sodium channel-blocking agents can significantly aggravate seizures in 1p36 deletion syndrome, particularly myoclonic seizures and infantile spasms[6][6][22][6]. The mechanistic basis for this aggravation relates to the presence of GABRD mutations in affected individuals; sodium channel blockade paradoxically worsens seizure control through mechanisms involving altered GABAergic inhibition[6][6][22][6].

A case series specifically examining the effect of carbamazepine in 1p36 deletion syndrome patients demonstrated clear seizure exacerbation, leading to the recommendation that CBZ should be avoided entirely[22]. This contraindication extends to other sodium channel-blocking agents, with oxcarbazepine similarly contraindicated[6][6][22][6].

#### Topiramate and Cognitive Concerns

Topiramate (TPM), acting through multiple mechanisms including carbonic anhydrase inhibition, sodium channel blockade, and GABA-A receptor potentiation, should be used with significant caution in 1p36 deletion syndrome[6][6][6][6]. While some patients with 1p36-associated infantile spasms have responded to topiramate in combination therapy or as monotherapy, the use of this agent carries substantial risk of accelerating cognitive decline, an already prominent feature of the syndrome[6][6][6][6]. Given the cognitive vulnerability of patients with 1p36 deletion syndrome, topiramate should be reserved for cases of refractory epilepsy where other options have been exhausted, and careful monitoring for cognitive deterioration is mandatory[6][6][6][6].

### Emerging and Investigational Antiepileptic Approaches

#### Bumetanide and NKCC1 Inhibition

Recent preclinical investigations have identified bumetanide, an inhibitor of the sodium-potassium-chloride cotransporter 1 (NKCC1), as a potentially beneficial agent for seizures associated with developmental disorders[6][6][14][6]. In animal models of Down syndrome, bumetanide reversed the excitatory GABA-A receptor signaling and restored inhibitory GABAergic currents, simultaneously enhancing learning and memory performance by restoring synaptic plasticity[6][6][14][6]. The rationale for bumetanide use in 1p36 deletion syndrome derives from similar mechanisms of impaired GABAergic inhibition through GABA-A receptor dysfunction.

While bumetanide has not yet been formally evaluated in clinical trials of 1p36 deletion syndrome, the mechanistic evidence and preclinical support suggest potential for future clinical translation[6][6][14][6]. This agent represents an emerging opportunity for pharmacological innovation in the management of seizures in this disorder, particularly given the limited efficacy of conventional antiepileptic drugs in many patients[6][6][14][6].

#### Gaboxadol (OV101): Investigational GABA-A Receptor Agonist

Gaboxadol, a selective agonist of benzodiazepine-insensitive GABA-A receptors containing δ4β and δ6β subunits, represents a novel investigational approach to 1p36 deletion syndrome[9][9]. This agent exhibits preferential efficacy at extrasynaptic rather than synaptic GABA-A receptors, contributing to tonic inhibitory conductances distinct from conventional benzodiazepine receptor agonists[9][9]. The mechanistic rationale for gaboxadol in 1p36 deletion syndrome derives from the prominent role of GABRD (GABA-A receptor delta subunit) dysfunction in this disorder, with gaboxadol potentially compensating for aberrant GABAergic signaling[9][9].

A patent application (US20210186938A1) describes methods and pharmaceutical compositions for treating 1p36 deletion syndrome with gaboxadol, specifying administration of approximately 5 mg to 50 mg of gaboxadol three times daily or 20-50 mg once to three times daily[9][9]. Extended-release formulations are proposed, providing therapeutic effects for more than six hours after administration[9][9]. Specific dosing recommendations for pediatric patients (ages 1 month to 18 years) range from approximately 1-15 mg administered once, twice, or three times daily, with transdermal formulations also contemplated[9][9].

However, gaboxadol experienced development setbacks in other indications. The compound initially advanced into late-stage development for insomnia treatment but discontinuation followed a three-month efficacy trial that failed to demonstrate significant effects on sleep onset and sleep maintenance[9][9]. Additionally, patients with a history of substance abuse who received gaboxadol experienced a marked increase in psychiatric adverse events[9][9]. These adverse effects limit enthusiasm for broad-based development in pediatric populations, though ongoing investigation for 1p36 deletion syndrome continues through more targeted mechanisms[9][9].

#### Ketogenic Diet Therapy

While not a pharmacological intervention in the traditional sense, ketogenic diet therapy and low-glycemic index treatment have demonstrated clinical efficacy for seizure management in 1p36 deletion syndrome, particularly in cases of refractory epilepsy unresponsive to multiple pharmacological agents[15][17][6]. Case reports and clinical observations document dramatic responses to diet therapy, including patients achieving seizure freedom within months following ketogenic diet implementation[15]. One documented case involved a patient whose seizure frequency decreased from 2-3 clusters daily to one cluster every 2-3 weeks following ketogenic diet initiation, followed by one year of seizure freedom[15].

The proposed mechanism of ketogenic diet efficacy relates to decreased neuronal excitability through multiple pathways, including GABA/glutamate ratio enhancement, adenosine triphosphate-sensitive potassium channel activation, and reduced mitochondrial reactive oxygen species production[15][6]. Given the frequent refractoriness of 1p36-associated seizures to pharmaceutical agents, ketogenic diet should be considered an important adjunctive treatment option, though implementation requires careful medical supervision due to the cardiac comorbidities prevalent in this population[15][17].

## Psychiatric and Behavioral Pharmacotherapy

### Sleep Disorder Management with Melatonin

Sleep disturbances represent a common comorbidity in 1p36 deletion syndrome, with some patients experiencing multiple nighttime wakings and difficulty resettling, requiring pharmacological intervention[1][1][17][1]. Melatonin, particularly in prolonged-release formulations (Slenyto®), has emerged as an effective off-label therapeutic option for sleep disorders in this population. A clinical case report documents treatment of a 4-year-old girl with 1p36.33–1p36.32 deletion, moderate intellectual disability, and severe insomnia with prolonged-release melatonin[1][1][1].

Treatment initiated at 1 mg daily, titrated to 2 mg daily, resulted in complete sleep normalization without adverse effects[1][1][1]. Outcome measures at follow-up (after 8 weeks of combined melatonin and methylphenidate treatment) revealed clinically significant reductions in sleep problems, with the Child Behavior Checklist (CBCL/1.5-5) scale demonstrating reliable change index (RCI) greater than 1.96 (RCI: 2.01)[1][1][1]. Sleep latency, sleep maintenance, and total sleep time all improved substantially, with sleep returning to normal age-appropriate ranges[1][1][1].

While Slenyto® (prolonged-release melatonin) is approved in Europe, Japan, and the United States for treatment of insomnia in subjects aged 2 to 18 years with autism spectrum disorders and/or Smith-Magenis syndrome where sleep hygiene measures are insufficient[1][1][1], it remains off-label for 1p36 deletion syndrome. However, the clinical experience documented in 1p36 patients suggests meaningful benefit despite lack of formal approval, with the reported absence of adverse effects supporting consideration of this therapeutic approach in patients with comorbid sleep disturbance[1][1][1].

### Attention-Deficit/Hyperactivity Disorder and Methylphenidate

Attention-deficit/hyperactivity disorder (ADHD) frequently comorbid with 1p36 deletion syndrome, has been managed off-label with methylphenidate in clinical practice[1][1][1]. A documented case of a 4-year-old girl with 1p36.33–1p36.32 deletion presenting with ADHD behaviors unresponsive to behavioral interventions alone received methylphenidate therapy[1][1][1].

Following parental informed consent and normal laboratory evaluation (including electrocardiogram), immediate-release methylphenidate initiated at 2.5 mg daily in the morning, titrated to 5 mg daily by dose escalation[1][1][1]. Clinical outcomes at daycare center demonstrated significant reduction in disruptive behavior problems, suggesting meaningful effect of methylphenidate at low dose for ADHD symptoms in the community setting[1][1][1]. Notably, no adverse effects were detected during methylphenidate treatment in this patient[1][1][1].

Methylphenidate-containing medications are approved in many countries for treatment of children aged six years and older and adolescents with ADHD as part of comprehensive treatment programs[1]. While the documented case involved off-label use in a younger patient (4 years old), the clinical rationale for stimulant therapy in ADHD within this population appears supported by the documented behavioral response[1][1][1]. However, careful patient selection, cardiac screening given the cardiac involvement frequent in 1p36 deletion syndrome, and close monitoring remain essential components of any methylphenidate use in this disorder[1][1][1].

### Parent-Child Interaction Therapy and Behavioral Interventions

Psychosocial interventions, particularly parent management training approaches, are recommended as first-line treatment for disruptive behavior disorders in preschool children and should precede or accompany pharmacological interventions in 1p36 deletion syndrome[1][1][1]. Parent-Child Interaction Therapy (PCIT) represents an evidence-based, manualized behavioral intervention specifically designed to help parents develop authoritative parenting styles while children develop self-regulation skills[1][1][1].

PCIT comprises distinct phases, with the Child-Directed Interaction (CDI) phase focusing on coaching parents to employ specific behavioral techniques labeled "PRIDE" skills—Praise (labeled praise), Reflection, Imitation, Description (behavioral description), and Enjoyment[1][1][1]. This approach combines play therapy and behavioral therapy modalities and demonstrates efficacy in children with developmental and intellectual disabilities[1][1][1]. In a comprehensive day clinic program combining PCIT with intensive interdisciplinary support (speech therapy, occupational therapy, individual psychotherapy, and educationalist intervention), clinically significant reductions in sleep problems and fewer disruptive behavior problems in family settings were achieved[1][1][1].

However, the clinical experience also documents that PCIT, while highly effective for some behavioral domains and in specific settings (such as daycare centers), may not fully resolve disruptive behaviors in all contexts or for all families[1][1][1]. In the documented case, disruptive behaviors in the family setting worsened again during outpatient follow-up despite previous day clinic treatment, suggesting that comprehensive behavioral management requires ongoing intervention and potential augmentation with pharmacological approaches when behavioral interventions alone prove insufficient[1][1][1].

## Cardiac Pharmacotherapy

### Management of Congenital Heart Defects

Cardiac involvement occurs in approximately 70 percent of patients with 1p36 deletion syndrome, with left-to-right shunt lesions (atrial septal defects and ventricular septal defects) representing the most prevalent abnormalities[12]. Patent ductus arteriosus occurs in approximately 20 percent, while cardiomyopathies (left ventricular noncompaction and dilated cardiomyopathy) comprise approximately 15 percent of cardiac abnormalities in this population[12].

Many congenital cardiac defects in 1p36 deletion syndrome demonstrate spontaneous resolution with time, while others require pharmacological management or surgical intervention[2][12]. Small septal defects frequently close spontaneously, and approximately half of patent ductus arteriosus cases resolve spontaneously within several months of birth[17]. When surgical intervention becomes necessary, careful perioperative management and long-term cardiac monitoring remain essential[2][12].

### Treatment of 1p36-Associated Cardiomyopathy

Dilated cardiomyopathy and left ventricular noncompaction represent particularly serious cardiac complications in 1p36 deletion syndrome, resulting from PRDM16 haploinsufficiency, and may present with acute decompensated heart failure in the neonatal period[12][13][18][18]. A documented case of a 15-month-old female with 1p36 deletion syndrome presenting with severe dilated cardiomyopathy and acute decompensated heart failure illustrates intensive pharmacological management approaches[18][18].

Initial management employed inotropic support with Milrinone infusion combined with diuretic therapy (Lasix and Diuril) and digoxin, subsequently transitioning to Ivabradine for rate control[18][18]. As cardiac function improved (ejection fraction 22% at presentation improved to 33% by day 10 of hospitalization), the inotropic agent was weaned and Captopril (ACE inhibitor) dosing increased[18][18]. By day 13 of admission, Carvedilol (beta-blocker) was added while Captopril transitioned to Enalapril and Digoxin was discontinued[18][18]. Long-term outpatient management consisted of oral heart failure medications including Lasix (diuretic), Enalapril (ACE inhibitor), and Carvedilol (beta-blocker), with Aspirin for antiplatelet effect[18][18].

This case demonstrates the principles of acute heart failure management adapted for the pediatric 1p36 deletion population, with emphasis on progressive reduction of inotropic support as cardiac function stabilizes and initiation of neurohormonal antagonism through ACE inhibition and beta-blockade[18][18]. Long-term prognosis requires close cardiologic follow-up with serial echocardiography and medication optimization[18][18].

### Prenatal Recognition and Early Intervention

Prenatal diagnosis of 1p36 deletion syndrome increasingly identifies cardiac anomalies including Ebstein's anomaly and other complex defects, as well as brain malformations on antenatal sonography[11][11]. A recent retrospective cohort analysis of 21 prenatally diagnosed 1p36 deletion cases (2017-2025) identified congenital brain anomalies (particularly ventriculomegaly) and cardiac defects as hallmark prenatal features, with Ebstein anomaly, increased nuchal translucency, and single umbilical artery representing additional potential indicators[11][11]. These prenatal findings should raise clinical suspicion and warrant confirmatory genetic testing, enabling anticipatory multidisciplinary planning including early pediatric cardiology involvement and counseling regarding potential neonatal interventions[11][11].

## Off-Label Psychotropic Medications and Behavioral Pharmacotherapy

### Antipsychotics and Mood Stabilizers

While limited literature specifically documents antipsychotic and mood stabilizer use in 1p36 deletion syndrome, clinical practice reflects off-label use of these agents for behavioral problems, emotional dysregulation, and aggression in some patients[1][1][1]. However, caution is warranted given reports of psychiatric medication as a risk factor for seizures in related chromosomal disorders[6][6][6]. Antipsychotic drugs most commonly associated with seizure precipitation include clozapine, phenothiazines, risperidone, and haloperidol, while among antidepressants, clomipramine carries elevated seizure risk[6][6][6].

Given the high seizure burden already present in 1p36 deletion syndrome, the use of psychiatric medications with proconvulsant properties represents a significant concern[6][6][6]. Therefore, careful risk-benefit analysis and consideration of alternative behavioral and psychosocial interventions remain essential before initiating such medications[1][1][1].

### Stimulant Medications Beyond ADHD

Stimulant medications including methylphenidate represent established treatments for ADHD in typical pediatric populations but are utilized off-label in 1p36 deletion syndrome for behavioral management beyond classical ADHD symptoms[1][1][1]. The documented case of methylphenidate use in a 4-year-old girl with comorbid ADHD and oppositional-defiant disorder demonstrates clinical benefit for disruptive behaviors in structured settings[1][1][1]. However, systematic data regarding stimulant use across broader behavioral indications in 1p36 deletion syndrome remain limited[1][1][1].

## Combination Therapy Approaches

### Multidrug Antiepileptic Regimens

Many patients with 1p36 deletion syndrome require polypharmacy for adequate seizure control, particularly those presenting with infantile spasms or experiencing refractory seizures[6][6][6][6]. The combination of valproate with lamotrigine has been specifically recommended for certain seizure presentations[6][6][6][6]. For infantile spasms, combination therapy utilizing both hormonal agents (ACTH or oral corticosteroids) and vigabatrin demonstrates substantially improved efficacy compared to monotherapy[10].

Beyond these established combinations, clinical practice frequently employs individualized polypharmacy based on seizure response and tolerability, though limited systematic data specifically characterizing optimal multidrug regimens in 1p36 deletion syndrome exist[6][6][6][6]. The principle of "therapeutic drug classes" rather than additive monotherapy remains relevant, favoring agents with distinct mechanisms of action to maximize seizure control while minimizing additive toxicity[6][6][6][6].

### Integrated Behavioral and Pharmacological Treatment

The documented clinical case of a 4-year-old girl with 1p36.33–1p36.32 deletion receiving integrated treatment including day clinic care with PCIT, melatonin for sleep, and methylphenidate for ADHD demonstrates the benefits of multimodal, coordinated intervention across behavioral, sleep, and neurodevelopmental domains[1][1][1]. This comprehensive approach, combining intensive psychosocial intervention with targeted pharmacological symptom management, achieved clinically significant improvements in sleep and behavioral outcomes[1][1][1].

However, the same case also illustrated the complexity of balancing multiple therapeutic interventions, as disruptive behaviors in the family setting worsened again despite previous improvements with day clinic treatment and medications[1][1][1]. This suggests that while combination therapy offers potential benefits, sustained coordination and ongoing adjustment of the therapeutic regimen remain necessary[1][1][1].

## Diagnostic Methods and Genetic Testing Considerations for Pharmacological Planning

### Chromosomal Microarray Analysis and Genetic Characterization

Accurate diagnosis of 1p36 deletion syndrome through chromosomal microarray analysis (CMA) enables precise characterization of deletion size and location, which increasingly demonstrates correlation with pharmacological response and adverse effect risk[5]. CMA provides resolution superior to conventional cytogenetic techniques, detecting deletions throughout the entire 30 Mb 1p36 region with precise genomic coordinates[5]. This genetic characterization informs understanding of which specific genes are deleted, predicting certain complications and guiding pharmacological selection[5].

For example, deletion of the PRDM16 gene specifically predicts cardiomyopathy risk and the need for cardiac medications and monitoring[5][13]. Deletion of GABRD predicts seizure susceptibility and need for appropriate antiepileptic drug selection[5][21][6]. Therefore, comprehensive genetic characterization using CMA or other molecular techniques should precede pharmacological planning in 1p36 deletion syndrome[5].

### Antenatal and Postnatal Diagnostic Approaches

Antenatal diagnosis of 1p36 deletion syndrome is feasible when a chromosome 1p36 rearrangement has been previously identified in a family member[5]. Fetal genetic testing using cell-free fetal DNA (noninvasive prenatal testing) or direct fetal sampling can identify 1p36 deletions[5]. First-trimester expanded noninvasive prenatal testing combined with fetal ultrasound has been successfully employed to diagnose 1p36 deletion syndrome in fetuses with sonographic findings of growth retardation and cardiac or brain anomalies[5][11][11].

Postnatal diagnosis typically involves karyotyping with high-resolution banding, fluorescence in situ hybridization (FISH), CMA, whole exome sequencing (WES), or whole genome sequencing (WGS)[5]. Modern sequencing approaches increasingly detect 1p36 deletions through software algorithms designed to identify copy number variations despite the sequencing techniques' primary design targeting single nucleotide variants[5].

## Clinical Trials and Emerging Therapies

### Current Clinical Trial Status

As of the current date (April 2026), limited active clinical trials are recruiting patients with 1p36 deletion syndrome[7]. A search of clinical trial registries identifies only one currently recruiting interventional trial for 1p36 deletion syndrome[7]. This paucity of active trials reflects both the rarity of the condition and the challenge of establishing efficacy endpoints and recruiting adequate sample sizes for studies in this heterogeneous disorder[7].

### SNP-Based Microdeletion Registry and Natural History Studies

The SNP-based Microdeletion and Aneuploidy Registry (NCT02381457) represents a completed observational study that has contributed substantially to understanding natural history and phenotypic variability in 1p36 deletion syndrome[24]. Ongoing registry and observational studies continue to accumulate data regarding longitudinal outcomes, genotype-phenotype correlations, and emerging therapeutic opportunities[24].

## Adverse Events, Drug-Drug Interactions, and Special Considerations

### Adverse Effects of Seizure Medications

Antiepileptic drugs employed in 1p36 deletion syndrome carry multiple potential adverse effects requiring careful monitoring[6][6][6][6]. Valproate carries teratogenic potential, requires hepatic monitoring, and can increase cognitive decline in some patients, thus necessitating careful risk-benefit analysis in female patients of reproductive potential[6][6][6][6]. Topiramate substantially increases risk of cognitive deterioration and carbonic anhydrase inhibitor-related metabolic acidosis, particularly problematic in a population already burdened with intellectual disability[6][6][6][6].

Levetiracetam may cause behavioral side effects including mood alterations and rarely psychosis, though these remain uncommon[6][6][6][6]. Phenobarbital produces significant sedation and cognitive impairment, reserving its use for refractory cases[6][6][6][6]. Vigabatrin carries the critical risk of irreversible peripheral visual field defects in approximately 30-40 percent of patients, though recent experience suggests lower rates than historically estimated[6][6][6][6][30].

### Cardiac Monitoring Requirements with Antiarrhythmics and Psychiatric Medications

Given the high prevalence of congenital heart defects and cardiomyopathy in 1p36 deletion syndrome, electrocardiographic screening is mandatory before initiating medications with potential cardiac effects[5][18][18]. Stimulant medications including methylphenidate require baseline electrocardiographic evaluation to exclude cardiac conduction abnormalities or structural lesions before initiation[1][1][1]. Similarly, certain antipsychotics and other psychiatric medications carry QT prolongation risk requiring baseline and periodic electrocardiographic monitoring[6][6][6].

### Pharmacokinetic Interactions and Polypharmacy Considerations

Patients with 1p36 deletion syndrome frequently require polypharmacy for management of multiple comorbidities (seizures, cardiac involvement, behavioral problems, sleep disturbance), necessitating careful attention to drug-drug interactions through shared metabolic pathways[6][6][6][6]. For example, valproate is a known inhibitor of multiple cytochrome P450 enzymes and can substantially increase concentrations of concomitant medications, while phenobarbital induces numerous metabolic pathways potentially reducing efficacy of other medications[6][6][6][6].

## Multidisciplinary Management Framework

### Comprehensive Care Coordination

Optimal pharmacological management of 1p36 deletion syndrome requires multidisciplinary coordination across numerous specialists including medical geneticists, neurologists (particularly epilepsy specialists), cardiologists, pediatricians, psychiatrists, developmental specialists, speech-language pathologists, occupational therapists, and physical therapists[1][2][5][8][1][1]. This multidisciplinary approach is mandatory to meet the complex needs of patients with this genetic disorder[1][1][1].

The integration of pharmacological and nonpharmacological interventions—combining antiepileptic drugs, cardiac medications, behavioral pharmacotherapy, and intensive psychosocial interventions—represents the standard of care[1][2][5][1][1]. Regular communication among team members regarding medication efficacy, tolerability, and emerging complications ensures coordinated optimization of the therapeutic regimen[1][1][1].

### Prenatal Counseling and Parental Support

For families receiving a prenatal diagnosis of 1p36 deletion syndrome, genetic counseling should address the complexity of the disorder, expected medical complications, prognosis regarding seizure risk and cardiac involvement, and anticipated need for long-term medical support[2][5][11][11]. Early discussions regarding anticipated pharmacological management of seizures and other complications enable informed decision-making and preparation for comprehensive postnatal care[2][5][11][11].

Parental support through multidisciplinary team engagement, psychosocial counseling, and parent management training programs like PCIT demonstrates substantial benefit in reducing parental stress, depression, and anxiety while improving child outcomes[1][1][1]. Training parents in behavioral management techniques and medication administration represents a crucial component of long-term management success[1][1][1].

## Conclusions and Future Directions

### Summary of Current Pharmacological Management

Chromosome 1p36 deletion syndrome remains a disorder without disease-specific approved pharmacotherapy; rather, management relies on evidence-based repurposing of drugs approved for other indications combined with off-label applications supported by clinical experience and mechanistic rationale[1][2][5][6][6][1][6][1][6]. Antiepileptic drugs, particularly valproate, levetiracetam, and lamotrigine, combined with standard first-line therapies for infantile spasms (ACTH and vigabatrin) represent the cornerstone of seizure management[6][10][6][6][6][27]. Cardiac medications including ACE inhibitors, beta-blockers, diuretics, and inotropic agents manage the frequent cardiomyopathy and heart failure complications[12][18][18].

Emerging pharmacological approaches including bumetanide for seizure management and investigational agents like gaboxadol targeting specific molecular mechanisms underlying the neurodevelopmental phenotype offer future therapeutic possibilities[6][9][6][14][9][6]. Psychiatric and behavioral pharmacotherapy, including melatonin for sleep disturbances and methylphenidate for ADHD, combined with evidence-based psychosocial interventions like PCIT, provide comprehensive behavioral and developmental support[1][1][1].

### Critical Gaps in Knowledge and Research Needs

Substantial gaps remain in understanding optimal pharmacological management of 1p36 deletion syndrome. Large-scale clinical trials specifically designed to evaluate pharmacological interventions in this population are absent, with most evidence derived from case reports, small case series, and extrapolation from experiences in related chromosomal disorders[1][6][6][1][6][1][6]. Systematic evaluation of antiepileptic drug efficacy, optimal dosing strategies, and long-term outcomes in 1p36 deletion syndrome would substantially improve evidence-based treatment guidance.

Additionally, the mechanistic basis of pharmacological responsiveness and the relationship between specific deleted genes and medication efficacy remain incompletely characterized. Future research employing sophisticated genotype-phenotype correlation, functional genomics, and animal modeling could identify novel drug targets and enable more personalized pharmacological approaches[6][9][6][14][6][6][9][6]. Finally, the potential for gene therapy approaches (including CRISPR-based therapies or other emerging technologies) to correct underlying genetic defects remains speculative but potentially transformative[32][34].

### Clinical Practice Recommendations

Based on available evidence, clinicians managing patients with 1p36 deletion syndrome should employ a systematic, multidisciplinary approach beginning with precise genetic characterization via chromosomal microarray analysis to define deletion boundaries and identify specific genes at risk for complications[5]. For seizure management, valproate or levetiracetam represent evidence-based first-line choices for non-infantile spasm seizures, with lamotrigine as an effective adjunct[6][6][6][6]. Infantile spasms should be managed urgently with ACTH or vigabatrin, considering combination therapy if monotherapy fails[10][27].

Carbamazepine and oxcarbazepine must be avoided due to high risk of seizure exacerbation[6][6][22][6]. Comprehensive cardiac screening including echocardiography, electrocardiography, and specialist consultation should be performed at diagnosis and regular intervals throughout childhood, with initiation of heart failure medications when cardiomyopathy is identified[2][5][12][18][18]. Sleep disturbances should be managed with behavioral interventions and consideration of melatonin when needed[1][1][1]. Disruptive behavioral disorders should first receive behavioral intervention through evidence-based programs like PCIT, with careful consideration of off-label psychotropic medications when behavioral interventions alone prove insufficient[1][1][1].

Regular clinical review and communication across the multidisciplinary team remain essential for optimizing outcomes and identifying emerging complications requiring therapeutic adjustment[1][2][5][1][1].